Streetwise Reports' Article Archives — April 2020 back to current month (31)
Algernon Pharmaceuticals reported it received approval from Health Canada for a Phase 2b/3 multinational clinical study of Ifenprodil in COVID-19 patients to prevent progression to intubation and mechanical ventilation.
Reliq Health Technologies reported that it has signed contracts to add eight new customers in Texas including an oncology practice that will be using its new iUGO Care Principal Care Management module.
Demand has been taking off for HealthSpace Data Systems' platform released two weeks ago.
Shares of Chimerix Inc. traded higher after the company reported it has received U.S. FDA clearance to initiate a Phase 2/3 Study of dociparstat sodium in acute lung injury for patients afflicted with severe COVID-19.
As contact tracing moves to center stage as a key to reopening the economy, HealthSpace releases a scalable cloud-based system that is rapidly being adopted, including by the state of Hawaii.
As the coronavirus pandemic has accelerated the move to telemedicine, two investment professionals are following CloudMD, a small cap rapidly expanding in Canada.
CloudMD Is My TeleHealth Stock (04/28/2020)
With telehealth becoming a rising star in the coronavirus era, Keith Schaefer discusses why one company rapidly expanding in Canada stands out.
SmileDirectClub shares traded 20% higher after the company reported it has been awarded a U.S. patent for its SmileShop retail concept and treatment process and that it plans to reopen stores on a rolling basis starting in May.
Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients.
Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its allogeneic cell therapy remestemcel-L.
Shares of West Pharmaceutical Services traded higher and established a new 52-week high price after the firm reported Q1/20 earnings that included a 10.8% increase in YoY revenues.
Algernon Pharmaceuticals will evaluate one of its drugs in coronavirus-infected patients with severe pneumonia.
The ways in which Moderna is to use the funds are explained and an update on its coronavirus vaccine is provided in a ROTH Capital Partners report.
The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report.
Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced renal cell carcinoma.
A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report.
Shares of Lifeway Foods traded higher as the company reported it has increased production to support accelerated demand during the COVID-19 health crisis.
Shares of MEI Pharma traded higher after the company announced that it has entered into development and global licensing agreement with Kyowa Kirin for its oral selective PI3Kδ inhibitor (ME-401) used for treating B-cell malignancies.
Shares of CytoSorbents traded higher setting a new 52-week intraday high price after the company reported that the FDA granted emergency use authorization for CytoSorb for use in patients with COVID-19.
Vir Biotechnology reported it has entered into an agreement with Samsung Biologics valued at $362 million for large-scale manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Though U.S. markets are closed for the Good Friday holiday, Samsung Biologics shares traded nearly 17% higher today on the Korean Stock exchange.
Shares of MediciNova traded higher after the company reported that it plans to initiate a clinical study of MN-166 (ibudilast) for COVID-19 acute respiratory distress syndrome.
Avivagen Inc. has secured its largest ever order of OxC-beta™ Livestock from its long-standing Philippine partner UNAHCO.
How this could be achieved using the proprietary platform of TFF Pharmaceuticals and why it could work are discussed in a ROTH Capital Partners report.
Shares of Novavax traded 20% higher setting a new 52-week high price after the company reported that it has accelerated initiation of a Phase 1 clinical trial for its coronavirus vaccine candidate NVX-CoV2373. The study will commence in mid-May with preliminary results expected in July 2020.
CloudMD attributed record weekly new user registrations to social distancing protocols and advised that it now has greater than 100,000 registered users on its telemedicine platforms.
Shares of Immunomedics opened 117% higher after the company reported that it has stopped its Phase 3 ASCENT study of sacituzumab govitecan after recording "compelling evidence of efficacy" in heavily pretreated patients with metastatic triple-negative breast cancer.
Animal Feed Supplement Maker Expands Asia Footprint (04/04/2020)
Avivagen receives new orders from two eastern countries for its product.
Shares of Fate Therapeutics traded higher after the firm reported it has treated the first patient in a first-in-human trial of FT596 for patients with B-cell malignancies and chronic lymphocytic leukemia.
Three COVID-19 Patients Treated with PLX Cells (04/01/2020)
Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report.
CloudMD reported that it has launched its telemedicine app in Ontario as coronavirus concerns have greatly increased the need for digital healthcare.
Chembio Diagnostics shares traded higher and set a new 52-week high price after the company reported that it has launched a DPP® COVID-19 serological point-of-care test which can deliver IgM/IgG antibody results in 15 minutes using a simple finger stick.
|"PMN's upside is relatively unlimited; it is rated an Immediate Buy."|